Martin, Andrew J.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,633

A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention

Chen, A. C., Martin, A. J., Choy, B., Fernández-Peñas, P., Dalziell, R. A., McKenzie, C. A., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Kricker, A., et al. (2015) · New England Journal of Medicine

Nonmelanoma Skin Cancer StudiesSkin Protection and Aging

Cited by 648

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 230

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., et al. (2024) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 195

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates

Kiely, B. E., Martin, A. J., Tattersall, M. H. N., Nowak, A. K., Goldstein, D., Wilcken, N. R. C., Wyld, D. K., Abdi, E. A., Glasgow, A., Beale, P. J., et al. (2013) · Journal of Clinical Oncology

Palliative Care and End-of-Life IssuesStatistical Methods in Epidemiology

Cited by 62

Cystocele recurrence after anterior colporrhaphy with and without mesh use

Wong, V., Shek, K. L., Goh, J., Krause, H., Martin, A., & Dietz, H. P. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology

Pelvic floor disorders treatmentsHernia repair and management

Cited by 52

Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients

Smith-Uffen, M. E. S., Johnson, S. B., Martin, A. J., Tattersall, M. H. N., Stockler, M. R., Bell, M. L., Detering, K., Clayton, J. M., Silvester, W., Clarke, S., et al. (2020) · Supportive Care in Cancer

Palliative Care and End-of-Life IssuesPatient-Provider Communication in Healthcare

Cited by 19

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 12